Ειδοποίηση Μελετητή:[ ΣΤΟΜΑΤΙΤΙΣ ]
The absence of an association between Interleukin 1β gene polymorphisms and recurrent aphthous stomatitis (RAS)
Z Ślebioda, A Kowalska, M Rozmiarek, E Krawiecka… - Archives of Oral Biology, 2017
Abstract Objectives Recurrent aphthous stomatitis (RAS) is a chronic, ulcerative disease with
a probable polygenic mode of inheritance and complex etiology with a strong immunological
background. The aim of the present study was to determine the possible association
a probable polygenic mode of inheritance and complex etiology with a strong immunological
background. The aim of the present study was to determine the possible association
Interleukin-2, Interferon-gamma Gene Polymorphisms in Recurrent Aphthous Stomatitis.
S Najafi, H Yousefi, M Mohammadzadeh, AZ Bidoki… - Prague medical report, 2017
Recurrent aphthous stomatitis (RAS) is the most common oral ulcerative inflammatory
disease with unknown etiology. IL-2 and IFN-γ are secreted by Th1 cells and the elevated
levels of them have been reported in RAS. Single nucleotide polymorphisms (SNPs) of IL-2
disease with unknown etiology. IL-2 and IFN-γ are secreted by Th1 cells and the elevated
levels of them have been reported in RAS. Single nucleotide polymorphisms (SNPs) of IL-2
279PReal-world everolimus experience in postmenopausal HR+ HER2-advanced breast cancer women: Treat ER+ ight Canadian prospective observational study …
C Doyle, N Califaretti, S Dent, E Chouinard, SR Perri… - Annals of Oncology, 2017
... enrolled pts since Mar '16 from 24 active sites. This sub-analysis describes baseline
characteristics, treatment duration and stomatitis prevention outcomes in EVE+EXE
pts. Results: Baseline characteristics: median age – 65 (39-80 ...
characteristics, treatment duration and stomatitis prevention outcomes in EVE+EXE
pts. Results: Baseline characteristics: median age – 65 (39-80 ...
Everolimus plus letrozole for treatment of patients with HR+, HER2–advanced breast cancer progressing on endocrine therapy: an open-label, phase 2 trial
T Safra, B Kaufman, L Kadouri, N Efrat, L Ryvo… - Clinical Breast Cancer, 2017
... DCR was achieved in 51 (85%) patients. The safety profile was consistent with previously
published data: The most frequently reported any grade adverse events (AEs) were fatigue (61.1%),
stomatitis (54.2%) and rash (33.4%). ... Fatigue, 61.1, 5.6, 0. Stomatitis, 54.2, 8.3, 0. ...
published data: The most frequently reported any grade adverse events (AEs) were fatigue (61.1%),
stomatitis (54.2%) and rash (33.4%). ... Fatigue, 61.1, 5.6, 0. Stomatitis, 54.2, 8.3, 0. ...
[PDF] Atypical Afta Major Healing after Photodynamic Therapy
C Casu, C Mannu - Case Reports in Dentistry, 2017
... original work is properly cited. Abstract. The aim of this study is to report a case of
atypical Afta Major healing in a patient with recurrent aphthous stomatitis (SAR) with
a type of photodynamic therapy. A female patient with SAR ...
atypical Afta Major healing in a patient with recurrent aphthous stomatitis (SAR) with
a type of photodynamic therapy. A female patient with SAR ...
237OA phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed …
YH Park, KH Lee, J Sohn, KS Lee, KH Jung, JH Kim… - Annals of Oncology, 2017
... The most common treatment-related AEs were (total/grade≥3) diarrhea
(96.23%/14.15%), stomatitis (92.45%/12.26%), and rash (63.21%/3.77%). ... Diarrhea
and stomatitis were the major toxicities leading to dose modification. ...
(96.23%/14.15%), stomatitis (92.45%/12.26%), and rash (63.21%/3.77%). ... Diarrhea
and stomatitis were the major toxicities leading to dose modification. ...
[PDF] REKÜRREN AFTÖZ STOMATİT TANILI HASTALARDA NÖTROFİL/LENFOSİT ORANI BİR AKUT FAZ REAKTANI OLARAK KULLANILABİLİR Mİ?
SP KARA, O AVCI, H ALBAYRAK, B TOPÇU… - 2017
... CAN THE NEUTROPHIL/LEUKOCYTE RATIO BE USED AS AN ACUTE PHASE REACTANT
IN PATIENTS DIAGNOSED WITH RECURRENT APHTHOUS STOMATITIS? ... Key Words: Recurrent
aphthous stomatitis, neutrophil/leukocyte ratio, c-reactive protein Page 2. 84 ...
IN PATIENTS DIAGNOSED WITH RECURRENT APHTHOUS STOMATITIS? ... Key Words: Recurrent
aphthous stomatitis, neutrophil/leukocyte ratio, c-reactive protein Page 2. 84 ...
[HTML] Desquamative Gingivitis
H Endo, TD Rees, H Niwa, K Kuyama, M Iijima… - Insights into Various …, 2017
... potential causes, such as lupus erythematosus [12], mixed connective tissue disease [5, 10],
graft versus host disease [13], erythema multiforme [14], epidermolysis bullosa [15, 16],
epidermolysis bullosa acquisita [17], Kindler syndrome [18], chronic ulcerative stomatitis [10, ...
graft versus host disease [13], erythema multiforme [14], epidermolysis bullosa [15, 16],
epidermolysis bullosa acquisita [17], Kindler syndrome [18], chronic ulcerative stomatitis [10, ...
[PDF] Caenorhabditis elegans as an Emerging Model for Virus-Host Interactions
DB Gammon - Journal of Virology, 2017
... 144 145 Vesicular Stomatitis virus 146 147 In 2005, two reports demonstrated that vesicular
stomatitis virus (VSV), an 148 arbovirus with broad invertebrate and vertebrate host range, could
replicate in 149 primary cells derived from C. elegans embryos (14, 16). ...
stomatitis virus (VSV), an 148 arbovirus with broad invertebrate and vertebrate host range, could
replicate in 149 primary cells derived from C. elegans embryos (14, 16). ...
1076PConcurrent chemoradiotherapy (CCRT) versus induction docetaxel, cisplatin and 5-fluorouracil (TPF) followed by CCRT in locally advanced hypopharyngeal …
SH Lim, JM Sun, J Hong, D Oh, YC Ahn, MK Chung… - Annals of Oncology, 2017
... In both subgroups with BOT and hypopharyngeal cancer, survival outcomes of IC arm were also
insignificantly superior to those of CRT arm. All adverse events were manageable and there was
no grade 3/4 toxicity except one patient had Gr3 stomatitis in IC arm. ...
insignificantly superior to those of CRT arm. All adverse events were manageable and there was
no grade 3/4 toxicity except one patient had Gr3 stomatitis in IC arm. ...
Αυτή η Ειδοποίηση του Μελετητή Google σας προσφέρεται από τη Google
Ακύρωση ειδοποίησης
Δημιουργία λίστας των ειδοποιήσεών μου
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου